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Breast cancer (BC) is the most common malignancy in 
women worldwide and estrogen-receptor (ER)-positivity 
is its hallmark in most patients. Even if outcome has 
improved over years, ER positive BCs may be resistant ab 
initio or become resistant to endocrine therapy later on. 
Many efforts have been made to improve clinical outcome 
of advanced ER-positive, human epidermal growth factor 
receptor 2 (HER2)-negative BC patients through the 
addition of signaling pathways inhibitors such as cyclin-
dependent kinases 4/6 (CDK4/6) inhibitors (ribociclib, 
palbociclib, abemaciclib). Upon stimulation with mitogenic 
signals, CDK4 and CDK6 form a complex with their 
regulatory subunit, cyclin D1, which phosphorylates the 
retinoblastoma protein (Rb), reducing its ability to suppress 
gene transcription (1). Controlled phosphorylation and 
deactivation of the Rb protein by the CDK4/6 complex is 
essential to progression of the normal cell cycle. In BC cells, 
uncontrolled CDK4/6 activity may result from alterations 
in the expression of cyclin-dependent kinases and their 
regulatory mechanisms. As a consequence, cell cycle 
stimulation leads to a growth advantage and to endocrine 
resistance (Figure 1).
In a recent article published on the New England Journal 
of Medicine, Hortobagyi et al. (2) reported the interim 
analysis of the MONALEESA-2 [Mammary Oncology 
Assessment of LEE011’s (Ribociclib’s) Efficacy and 
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Safety-2] trial. This study included 668 postmenopausal 
patients treated with non-steroidal aromatase inhibitor 
letrozole plus the CDK4/6 inhibitor ribociclib or placebo 
as first-line therapy for metastatic disease. About 30% 
of the enrolled patients had newly diagnosed advanced 
or metastatic disease and near 60% of the patients had 
visceral disease. More than 50% of patients received 
prior adjuvant endocrine therapy (tamoxifen in about 
40% of patients). Near half of patients had received 
prior adjuvant chemotherapy. In MONALEESA-2 
trial, the addition of ribociclib to letrozole significantly 
improved progression-free survival (PFS) at 18 months 
in comparison with letrozole and placebo (63.0% vs. 
42.2%; hazard ratio for disease progression or death, 0.56; 
95% CI, 0.43–0.72). Moreover, the vast majority (80%) 
of patients treated with the CDK4/6 inhibitor ribociclib 
obtained a clinical benefit (CB) defined as absence of 
disease progression. Overall survival has not been reported 
yet in MONALEESA-2 trial. The most common adverse 
events were neutropenia (74.3% in the ribociclib group 
and 5.2% in the placebo group), nausea (51.5% and 28.5%, 
respectively), infections (50.3% and 42.4%), fatigue (36.5% 
and 30.0%), and diarrhea (35.0% and 22.1%). Nausea, 
infections, fatigue, and diarrhea were mostly grade 1 or 
2. The most common grade 3 or 4 adverse events were 
neutropenia (59.3% in the ribociclib group and 0.9% in the 
placebo group); febrile neutropenia occurred, however, only 
in five patients (1.5%) in the ribociclib group; hypertension 
(9.9% and 10.9%) and increased alanine amino-transferase 
level (9.3% and 1.2%). QTc interval prolongation was 
observed only in the ribociclib group (3.3%). Importantly, 
about 30% of the patients enrolled in the MONALEESA-2 
trial and assigned to ribociclib required drug reductions. 
Despite this most patients (>90%) were able to continue 
treatment with ribociclib without withdrawal. Overall, 
serious adverse events (SAE) occurred in 71 patients (21.3%) 
in the ribociclib group and in 39 (11.8%) in the placebo 
group. Of these events, 25 (7.5%) in the ribociclib group 
and 5 (1.5%) in the placebo group were possibly related 
to the study regimen. There were 4 deaths [3 (0.9%) in 
the ribociclib group and 1 (0.3%) in the placebo group] 
during treatment. Noteworthy, similar results in terms of 
safety and efficacy were obtained with the other CDK4/6 
inhibitor palbociclib (Ibrance; Pfizer), which was tested 
in association with fulvestrant the recently published 
randomized phase III trial PALOMA-3 (3). Moreover, 
similarly to the MONALEESA-2 trial, in PALOMA-3 trial, 
dose modifications did not appear to affect PFS. Currently, 
based on the above study, ribociclib has been submitted for 
FDA approval in combination with anti-estrogen therapy 
for advanced HR-positive, HER2 negative BC. Palbociclib 
received FDA approval last year in the same setting. Several 
trials with a third CDK4/6 inhibitor (abemaciclib) are 
ongoing in association with other endocrine therapies such 
Figure 1 CDK 4/6 inhibitors. CDK 4/6, cyclin-dependent kinases 4/6; G1, cell cycle, G1 phase; G2, cell cycle, G2 phase; M, cell cycle, M 
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as fulvestrant (ClinicalTrials.gov number, NCT02107703) 
and aromatase inhibitors (NCT02246621) on the basis of 
an FDA “breakthrough therapy” designation, a process 
designated to expedite the development and review of 
drugs that are intended to treat a serious condition and 
preliminary clinical evidence indicates that the drug may 
demonstrate substantial improvement over clinically 
available therapy (4). 
Efforts at elucidating the molecular mechanisms of 
endocrine resistance have revealed a number of targets 
that act downstream or upstream or crosstalk with ER 
pathway (4). Consequently, several agents have been 
developed with the aim of interfering with the ability of 
ER-positive cancer cells to resist to endocrine therapy such 
as inhibitors of the PI3K/AKT/mTOR pathway (5) and 
histone deacetylase inhibitors (6). In particular, the rationale 
of combining endocrine therapy with therapeutic agents 
able to prevent, delay or circumvent endocrine resistance 
has been, and is being tested in several phase II and III 
trials. In this context, results with CDK4/6 inhibitors 
from randomized phase III trials MONALEESA-2 and 
PALOMA 3 could be seen as ‘practice changing’ on the 
basis of efficacy. However, beyond the increase in median 
PFS, the positive studies reported consistent increases in 
ORR, and a substantial increase in clinical benefit rate 
(CBR), resulting from more patients achieving long-lasting 
stable disease with the combined treatment. However, the 
follow-up of MONALEESA-2 and PALOMA 3 is still too 
short to adequately evaluate overall survival (OS). This 
is particularly important because, benefits from adding a 
biologic agent to endocrine therapy add toxicities and costs. 
Waiting for OS results, the main question is whether a PFS 
advantage supports the widespread use of these compounds 
in the everyday clinical practice and across the whole 
clinical spectrum of HR+/HER2− MBC patients. Tumor 
regression and PFS prolongation may have positive effects 
in patients whose disease is symptomatic, but it may not 
be true in asymptomatic patients. Furthermore, delaying 
the use of “conventional” chemotherapy could be seen 
as a goal of endocrine therapy. However, this prolonged 
‘chemotherapy-free interval’ is filled in with additional 
toxicities and a clinical management consisting of more 
frequent hospital visits, lab works, and staging procedures, 
which are commonly associated with “conventional” 
chemotherapy. The decision to continue or stop a certain 
treatment is multifactorial and does take into account not 
only antitumor activity, but also tumor-related symptoms 
evolution, treatment-related toxicities, costs, and patient’ 
wishes. With these premises, especially in the era of 
precision medicine, identification and validation of predictive 
biomarkers that could allow treatment tailoring and toxicity 
sparing are really crucial. Nowadays, however, HRs and 
HER2 are the only biomarkers used to select patients for 
combinations of biologics with endocrine therapy. Most of 
the clinical trials that have led to the registration of biologics 
in association with to endocrine therapy, included extensive 
biomarker evaluations but rarely results were consistent 
with preclinical evidence. For example, considering cyclin-
dependent kinases 4/6 (CDK 4/6) inhibitors, preclinical data 
and phase 1 studies suggested that CCND1 amplification 
or p16 loss was predictive of response, but the phase 2 
PALOMA 1 study, which was designed to specifically address 
this issue, showed equal benefit of palbociclib, regardless of 
their status in neoplastic tissue (7). On the other hand, the 
BELLE-2 trial showed that PIK3CA mutations in ctDNA 
predict the activity of buparlisib therefore suggesting that the 
status of this biomarker could be assessed before treatment (8). 
In this respect, liquid biopsy is a pivotal technology. 
In conclusion, randomized phase III trials have shown 
that CDK4/6 inhibitors are effective in HR positive BC but 
newer studies including predefined biomarker-based design 
are needed to validate the efficacy of CDK4/6 inhibitors 
in molecularly defined patients’ subsets. We hope that the 
ongoing translational efforts, building on previous failure and 
with the support of innovative trial design and technologies, 
will result in a better understanding of the genetic alterations 
or pathways activations to improve treatment personalization. 
Defining populations with a specific alteration in a given 
signaling pathway could improve the likelihood of benefit 
from a targeted agent, limit unnecessary toxicities, and allow 
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